Biohaven didn't receive the clinical readout it was hoping for over the festive period. | As the biopharma wound down for the ...

Gilgamesh Pharma, a clinical-stage neuroscience company focused on transforming psychiatric treatment, today announced positive topline results from its Phase 2a study of blixeprodil (GM-1020).

Depression, one of the most prevalent mental health disorders worldwide, is characterized by persistent feelings of sadness, ...

An analysis of major depressive disorder, covering diagnostic criteria, prevalence statistics across demographics, and ...

Biohaven Ltd. recently reported that its Phase 2 proof-of-concept trial of BHV-7000 for major depressive disorder failed to meet the primary MADRS endpoint over six weeks versus placebo, although the ...

Overall tolerability and safety were observed, with adverse events primarily mild or moderate and resolving spontaneously.

Adding a daily fish oil supplement to psychotherapy showed no significant benefit over placebo for kids and teens with ...

Patients with first-episode MDD showed lower effective and functional connectivity between the anterior cingulate cortex and frontal regions.

Intra-Cellular Therapies’ surging antipsychotic Caplyta has scored again with remarkable trial results, fueling its bid for a third and potentially most lucrative indication—major depressive disorder ...

—Jonathan R. I. Coleman, PhD, discusses the genetic correlation between MDD and PTSD, which seems to hover at roughly 65%. But the story may be more complicated. Posttraumatic stress disorder (PTSD) ...